Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): Important aspects with regard to clinical use
2013.06.20
Active substance: lenalidomide
Celgene Europe Ltd. is sending out information on important aspects regarding the clinical use of Revlimid® (lenalidomide) for which a further indication was recently licenced.
updated
(June 2013) - available in German only
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN